Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats

Neuropharmacology

Volumn 56, Issue 4, 2009, Pages 761-767

  Di Benedetto, Manuela ^a   Cavina, Chiara ^a   D'Addario, Claudio ^a   Leoni, Giorgia ^a   Candeletti, Sanzio ^a   Cox, Brian M ^b   Romualdi, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

6 OHDA; Caudate putamen (CP); MPP+; Nociceptin (N OFQ); NOPr; Parkinson's disease; Substantia nigra (SN)

Indexed keywords

GLUTAMATE DECARBOXYLASE; NOCICEPTIN; NOCICEPTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PUTAMEN; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BLOTTING, WESTERN; CAUDATE NUCLEUS; GENE EXPRESSION; GLUTAMATE DECARBOXYLASE; MALE; MPTP POISONING; OPIOID PEPTIDES; OXIDOPAMINE; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 60149097710     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.12.009     Document Type: Article

References (38)

1. Albrecht D., Bluhdorn R., Seigmund H., Berger H., and Calo G. Inhibitory action of nociceptin/orphanin FQ on functionally different thalamic neurons in urethane-anesthetized rats. Br. J. Pharmacol. 134 (2001) 333-342
2. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
3. von Bohlen Und Halbach O. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 318 (2004) 163-174
4. Brown J.M., Gouty S., Iyer V., Rosenberger J., and Cox B.M. Differential protection against MPTP or methamphetamine toxicity in DA neurons by deletion of ppN/OFQ expression. J. Neurochem. 98 (2006) 495-505
5. Calò G., Rizzi A., Rizzi D., Bigoni R., Guerrini R., Marzola G., Marti M., McDonald J., Morari M., Lambert D.G., Salvadori S., and Regoli D. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 136 (2002) 303-311
6. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
7. Emborg M.E., Carbon M., Holden J.E., During M.J., Ma Y., Tang C., Moirano J., Fitzsimons H., Roitberg B.Z., Tuccar E., Roberts A., Kaplitt M.G., and Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 27 (2007) 501-509
8. Erlander M.G., Tillakaratne N.J., Feldblum S., Patel N., and Tobin A.J. Two genes encode distinct glutamate decarboxylases. Neuron 7 (1991) 91-100
9. Gasser T. Genetics of Parkinson's disease. Clin. Genet. 54 (1998) 259-265
10. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 (1998) 1346-1350
11. Hamani C., Saint-Cyr J.A., Fraser J., Kaplitt M., and Lozano A.M. The subthalamic nucleus in the context of movement disorders. Brain 127 (2004) 4-20
12. Heikkila R.E., Cabbat F.S., Manzino L., and Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology 23 (1984) 711-713
13. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
14. Kaplitt M.G., Leone P., Samulski R.J., Xiao X., Pfaff D.W., O'Malley K.L., and During M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8 (1994) 148-154
15. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., and Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J. Med. Chem. 42 (1999) 5061-5063
16. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
17. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339 (1998) 1130-1143
18. Langston J.W., and Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. (1983) 309-310
19. Lee B., Lee H., Nam Y.R., Oh J.H., Cho Y.H., and Chang J.W. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther. 12 (2005) 1215-1222
20. Luo J., Kaplitt M.G., Fitzsimons H.L., Zuzga D.S., Liu Y., Oshinsky M.L., and During M.J. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 (2002) 425-429
21. Maidment N.T., Chen Y., Tan A.M., Murphy N.P., and Leslie F.M. Rat ventral midbrain dopamine neurons express the orphanin FQ/nociceptin receptor ORL-1. Neuroreport 13 (2002) 1137-1140
22. Marin C., Aguilar E., and Obeso J.A. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov. Disord. 21 (2006) 646-653
23. Marti M., Guerrini R., Beani L., Bianchi C., and Morari M. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112 (2002) 153-160
24. Marti M., Mela F., Guerrini R., Calò G., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 91 (2004) 1501-1504
25. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., and Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24 (2005) 6659-6666
26. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27 (2007) 1297-1307
27. Meis S., and Pape H.C. Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala. J. Physiol. (Lond.) 532 (2001) 701-712
28. Menegon A., Board P.G., Blackbum A.C., Mellick G.D., and Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 (1998) 1344-1346
29. Neal Jr. C.R., Mansour A., Reinscheid R., Nothacker H.P., Civelli O., Akil H., and Watson Jr. S.J. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J. Comp. Neurol. 412 (1999) 563-605
30. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
31. Norton C.S., Neal C.R., Kumar S., Akil H., and Watson S.J. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J. Comp. Neurol. 444 (2002) 358-368
32. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Macias R., Alvarez L., Guridi J., Vitek J., and DeLong M.R. Pathophysiologic basis of surgery for Parkinson's disease. Neurology 55 Suppl. 6 (2000) S7-S12
33. Tipton K.F., and Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61 (1993) 1191-1206
34. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 (1968) 107-110
35. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367 (1971) 95-122
36. Wichmann T., and DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. N. Y. Acad. Sci. 991 (2003) 199-213
37. Windels F., and Kiyatkin E.A. GABA, not glutamate, controls the activity of substantia nigra reticulata neurons in awake, unrestrained rats. J. Neurosci. 24 (2004) 6751-6754
38. Zheng F., Grandy D.K., and Johnson S.W. Actions of orphanin FQ/nociceptin on rat ventral tegmental neurons in vitro. Br. J. Pharmacol. 136 (2002) 1065-1071